Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab versus vedolizumab in targeted-therapy-naive adults with moderate to severe ulcerative colitis
2024-518998-33-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 33
01
Overview
Phase 3, randomised, open-label trial in autoimmune colitis comparing Risankizumab with Vedolizumab (2 arms). Primary endpoint: Endoscopic improvement at Week 48. Planned start Jul 2025; status: authorised.
02
Drugs
risankizumabvedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2024-518998-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518998-33-00.